Buy Jupiter Life Line Hospitals Ltd for Target Rs. 1,645 by Choice Institutional Equities
Long-term capacity expansion — taking bed count to almost 3×: JLHL is scaling up, from 1,048 beds across 3 hospitals today to ~2,900 beds across 7 hospitals by FY31E — ~170% capacity addition. All greenfields exclusively target Western India's most underserved micro-markets. Execution risk is comprehensively de-risked: Dombivli delivered on budget at INR 4,250 Mn and a quarter ahead of guidance, replicating three previous successful ramp-ups at Thane (72.1% occupancy), Pune (65.5%) and Indore (54.9% and still growing). EBITDA breakeven at Dombivli is targeted by end of Year 2 (FY28E). Every hospital operates as a fully independent tertiary-quaternary hub offering over 30 specialties, driving consolidated ARPOB from INR 43,946 in FY21 to INR 68,000 in Q3FY26, with zero dependence on spoke.
Strong payor mix - negligible government scheme exposure: JLHL’s strong payor mix has 1.1% from government schemes in 9MFY26, insurance at 55.7% and selfpay at 43.2%. Negligible CGHS empanelment and no participation in the common empanelment programme makes it a permanent strategic choice, not a temporary positioning. Insurance contracts are renewed annually at inflation-linked rates, providing a contractual ARPOB which compounds from the current INR 68,000 base in Q3FY26. Debtor days of just 13 and negligible government receivable provisioning risk confirm that payor translates directly into cash. As Dombivli, Pune South, Mira Road and BKC commission into the same payor framework, blended network collections and working capital efficiency will only strengthen further
Strong balance sheet gives opportunity for inorganic growth: JLHL's approved borrowing ceiling of INR 6,000 Mn, with only INR 3,500 Mn drawn post-Dombivli, leaves INR 2,500 Mn of pre-authorised, immediately deployable acquisition capital. Balance sheet remains underleveraged at 0.24x D/E and 22.7x interest coverage, providing headroom to fund Pune South (INR 5,000 Mn), Mira Road (INR 3,000 Mn), BKC (INR 5,000 Mn) and other inorganic acquisitions. Company-owned land for 6 out of 7 hospital (except BKC) eliminates future lease liability, protecting EBITDA margin. Annualised FY26E EBITDA of INR ~3,350 Mn and debtor days of 13, confirm that every future hospital, greenfield or acquired, will be funded from JLHL's own compounding cash generation engine.
Investment View: We expect Revenue/EBITDA/PAT to expand at a CAGR of 26.3%/25.7%/28.5% over FY26-29E, driven by a bed capacity expansion of around 3x, an industry-leading payor mix with negligible government scheme exposure and a robust balance sheet, which leads to significant headroom for inorganic growth. Thus, we initiate coverage on JLHL with a BUY recommendation and target price of INR 1,645, with an upside of 37.1%, by valuing the company on DCF (including the BKC expansion plan), implying an EV/EBITDA multiple of 18.8/15.6 at FY28E/FY29E. DCF assumptions: Revenue Growth of CAGR 20.1% and EBIT growth of CAGR 21% considered from FY26–36E.
Optionality: JLHL is open to inorganic opportunities within Western India; any brownfield acquisition could provide faster bed addition and earnings accretion
Key risks: Location selection, if conviction on a micro-market geography turns out to be wrong, and possible delay in the upcoming projects execution.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
